텔릭스팜즈(TLX) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 텔릭스팜즈(TLX)?

텔릭스팜즈(TLX) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of TLX?

The market cap of TLX is approximately $3.4B, ranking 1,702 within its sector.

Q: What is the 52-week high and low for TLX?

TLX has recorded a 52-week high of $14.27 and a low of $6.28.

TLX

Telix Pharmaceuticals Ltd ADR

7월 27일 4:00 PM ET (한국 7/28 05:00)

$9.98

-0.24 ▼ -2.35%

🌙 7월 27일 7:39 PM ET (한국 7/28 08:39)

$10.17

+0.19 ▲ +1.90%

텔릭스팜즈(TLX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$3.4B

스몰캡

P/E

배당수익률

없음

52주 위치

46%

저점 +59% · 고점 -30%

애널리스트

적극 매수

Fundamental health

vs. Biotechnology 중형주

수익성

Top 53%

성장

Top 5%

밸류에이션

Top 42%

재무 안정

Top 48%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.02	Insider Own ⓘ	-	Shs Outstand ⓘ	334.1M	Perf Week ⓘ	-5.04%
Market Cap ⓘ	3.39B	Forward P/E ⓘ	106.9	EPS next Y ⓘ	119.25%	Insider Trans ⓘ	-	Shs Float ⓘ	-	Perf Month ⓘ	-8.1%
Enterprise Value ⓘ	3.72B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	0.82%	Short Float ⓘ	-	Perf Quarter ⓘ	-5.49%
Income ⓘ	-0.01B	P/S ⓘ	4.21	EPS this Y ⓘ	301.82%	Inst Trans ⓘ	-6.51%	Short Ratio ⓘ	1.8	Perf Half Y ⓘ	31.14%
Sales ⓘ	0.80B	P/B ⓘ	8.14	EPS next 5Y ⓘ	-	ROA ⓘ	-0.67%	Short Interest ⓘ	0.30M	Perf YTD ⓘ	33.24%
Book/sh ⓘ	1.23	P/C ⓘ	23.9	EPS past 3/5Y ⓘ	55.05% 29.38%	ROE ⓘ	-1.86%	52W High ⓘ	-30.06% ($14.27)	Perf Year ⓘ	-29.72%
Cash/sh ⓘ	0.42	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	93.54% 195.21%	ROIC ⓘ	-0.83%	52W Low ⓘ	58.92% ($6.28)	Perf 3Y ⓘ	-
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	94.83	EPS Y/Y TTM ⓘ	-121.18%	Gross Margin ⓘ	53.15%	Volatility(W/M) ⓘ	2.19% 2.32%	Perf 5Y ⓘ	-
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.62	Sales Y/Y TTM ⓘ	55.73%	Oper. Margin ⓘ	2.2%	ATR (14) ⓘ	0.39	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	1.27	EPS Q/Q ⓘ	-	Profit Margin ⓘ	-0.89%	RSI (14) ⓘ	40.57	Recom ⓘ	1.33
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1.43	Sales Q/Q ⓘ	-	SMA20 ⓘ	-10.06% ($11.1)	Beta ⓘ	-0.21	Target Price ⓘ	$17.45
Payout ⓘ	-	Debt/Eq ⓘ	1.12	Earnings ⓘ	2026/2/19	SMA50 ⓘ	-3.51% ($10.34)	Rel Volume ⓘ	0.64	Prev Close ⓘ	$10.22
Employees ⓘ	1184	LT Debt/Eq ⓘ	1.08	EPS/Sales Surpr. ⓘ	-158.23% -1.22%	SMA200 ⓘ	7.3% ($9.3)	Avg Volume(3M) ⓘ	0.16M	Price ⓘ	$9.98
IPO ⓘ	2024/11/14	Option/Short ⓘ	No/Yes			Trades ⓘ	1935	Volume ⓘ	106,266	Change ⓘ	-2.35%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Telix Pharmaceuticals Ltd ADR (TLX) Investment Analysis

What kind of company is Telix Pharmaceuticals Ltd ADR?

텔릭스팜즈(TLX) 초고성장주

Healthcare · Biotechnology

#1702 by Market Cap — Mid-Cap

☢️ This is an Australia-based biopharmaceutical company that develops and sells radiopharmaceuticals. It commercializes and sells radiopharmaceuticals for cancer diagnostics, including prostate cancer, and develops radiopharmaceuticals for cancer treatment, giving it exposure to demand for radiopharmaceuticals. The company operates in the radiopharmaceutical sector.

Learn more about Telix Pharmaceuticals Ltd ADR →

Market Cap

$3.4B

Approx. KRW 4.6 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank1702

Employees1,184people

IPO2024/11/14

Current Price$9.98 ≈ 13,673원

NASD · Australia

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 2월 19일 (목) · 장 마감 후 EPS -158.2% 매출 -1.2%

Is it profitable?

Profitability weak

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

2.2%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 중형주 Median -140.2% · Top 24%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-0.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

53.1%

✓ 부진

My positionBottom 25%

Low range Average High range

Biotechnology 중형주 Median 82.6% · Bottom 19%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-1.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-0.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-0.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

1.12

✓ Average

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.43

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

1.27

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$17.45

현재가 대비 +74.8%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

106.90배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+119.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-158.2%

평균 서프라이즈

2026.02.19

하회

-158.2%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+301.8%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 49.3% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+119.3%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 31.3% · Top 4%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+55.0%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 0.8% · Top tier

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+29.4%

우수

My positionTop 25%

Low range Average High range

초고성장주 중형주 Median 1.9% · Top 22%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+195.2%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 30.4% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 46%p over the past year

TLX -29.7% · S&P 500 +16.0%

Excess return vs. market (price-based, ex-dividends)

1-year basis

vs S&P 500

-45.7%p

Significantly behind the market

vs Health Care (XLV)

-49.4%p

Significantly behind the sector average

Rank among peers

1-year return Lowest among peers Based on 76 peers

Current position within 52-week range

Low (-58.9%p) High (-30.1%p)

Current price is 58.9% above the 52-week low and 30.1% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-22.1%

Annualized volatility

57.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $9.98 below the midline ($11.10). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.067 < Signal 0.111 in negative zone + Hist negative (-0.178). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 40.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 4.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales, Pricey on Vs. Earnings·Vs. Cash Flow, In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

106.90x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 중형주 median 27.75x · Bottom 13% — expensive within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

8.14x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 중형주 median 6.81x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

4.21x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 중형주 median 23.18x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

94.83x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology median 22.58x · Bottom 11% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

Analyst target price (reference)

$17.45 vs. current price +74.8%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership flow shows some pressure

Institutional net selling -6.5%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

No trading data for Insiders

🏦 Institutions (funds & investors)

-6.5%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 0.8%

Retail-led

Healthcare 중형주 Median 89.4%

👤 Retail investors (estimated) 99.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

Short interest days to cover

1.8 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 334.1M주

Float (tradable shares) -

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 0 days.

ETFs holding TLX

ETFs with the highest weightings · 10 total shown

ISCF

iShares International Small-Cap Equity Factor ETF

0.16%

$649M

FLAU

Franklin FTSE Australia ETF

0.15%

$172M

SCZ

iShares MSCI EAFE Small-Cap ETF

0.08%

$13.1B

IPAC

iShares Core MSCI Pacific ETF

0.03%

$2.6B

WSML

iShares MSCI World Small-Cap ETF

0.02%

$651M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TLX This Stock	$3.4B	-	8.1 ▼	-1.86% ▲	-	-2.4%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 텔릭스팜즈(TLX)?

텔릭스팜즈(TLX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TLX?

The market cap of TLX is approximately $3.4B, ranking 1,702 within its sector.

What is the 52-week high and low for TLX?

TLX has recorded a 52-week high of $14.27 and a low of $6.28.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.